IBS Market to Triple to $1.52bn by 2018

15 March 2010 (Last Updated March 15th, 2010 18:30)

The irritable bowel syndrome (IBS) drug market in the US, Europe and Japan will more than triple from $459m in 2008 to $1.52bn in 2018, according to a new report. The Decision Resources report found that the market in the US, France, Germany, Italy, Spain, the UK and Japan can expect larg

The irritable bowel syndrome (IBS) drug market in the US, Europe and Japan will more than triple from $459m in 2008 to $1.52bn in 2018, according to a new report.

The Decision Resources report found that the market in the US, France, Germany, Italy, Spain, the UK and Japan can expect large-scale growth mostly on the back of several novel first-in-class therapy launches, expected from 2011 onwards.

The new drugs include including Salix's Xifaxan, Ironwood/Forest/Almirall/Astellas's linaclotide, Tioga/Ono's asimadoline and Lexicon/Symphony Icon's LX-1031.

Two of these therapies in particular, linaclotide and asimadoline, have the potential to treat motility and pain symptoms associated with IBS, which will afford them a distinct advantage over available drugs, according to the report.

Decision Resources analyst Iva Holder said that linaclotide will enter the highly underserved market for constipation-predominant IBS and with launches anticipated in the US and Europe, it is forecast to be a major contributor to market growth.

"Although linaclotide will capture a relatively small percentage of the total patient share, it will account for 40% of overall market sales in 2018 due to its premium pricing," Holder said.

The Pharmacor 2010 report also points to concerns about serious side effects associated with 5-HT-receptor-modulating therapies, which have created a much stricter and challenging regulatory environment for developers of treatments for IBS.

As a result, few new therapies have reached the market in recent years, creating further opportunity for the development of novel therapies for the indication.